Skip to main content
Recurrent Illness and the Burden of COVID-19
31, Dec 2020

Recurrent Illness and the Burden of COVID-19

Recurring symptoms lasting several months may require ongoing treatment in some patients who have experienced COVID-19 infection. Terms referring to this condition include “long-haul COVID-19” or COVID-19 readmissions.

 

Source: https://www.nytimes.com/2020/12/30/health/covid-hospital-readmissions.html?action=click&module=Top%20Stories&pgtype=Homepage 

 

The CDC Report: For the period March-August 2020, the CDC’s MMWR Morbidity and Mortality Weekly Report 2020;69:1695–1699 reviewed the progress of 126,137 unique COVID-19 infection patients admitted to US hospitals between March-July 2020. Fifteen percent of these patients died. 

Among 106,543 survivors, 

  • 9% were readmitted to the same hospital within 2 months, and 1.6% were readmitted more than once, for recurrent illness. 
  • Readmitted patients tended to be >65 years old, with chronic conditions,  with previous hospitalizations in the 3 months prior to the COVID-19 infection, and had been discharged to a skilled nursing facility, or with home healthcare.  

 

Source: http://dx.doi.org/10.15585/mmwr.mm6945e2external icon

 

 

VA Hospitals confirm these COVID-19 readmissions: 2179 hospitalized COVID-19 patients in 132 VA hospitals were followed for progress. 

  • Among survivors who were discharged, a fifth were readmitted within 60 days. These patients tended to be older than those not requiring readmission. 
  • Reasons for readmission included COVID-19 in 30%, sepsis in 8%, pneumonia in 3%, and heart failure in 3%. 
  • COVID-19 survivors had higher readmission rates within the first 10 days after the first admission than matched survivors of pneumonia and heart failure without COVID-19.   

 

Source: 

https://jamanetwork.com/journals/jama/fullarticle/2774380?guestaccesskey=3805b67d-afd3-40ee-afb7-0a06914cece2&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=121420&alert=article 

 

The toll of COVID-19 infection and COVID-19 readmissions: Among 1648 COVID-19 patients admitted to 38 hospitals in Michigan with COVID-19 infection 75% survived and were discharged. 

  • In the 60 days after discharge, an additional 7% died, and 15% had to be readmitted. 

 

Among survivors interviewed 60 or more days after discharge:

  • A third reported cardiopulmonary symptoms 
  • 13% reported a persistent loss of taste or smell
  • 40% of previously employed individuals could not return to work because of persistent health issues or loss of employment
  • 26% of those who returned to work could not do so full time.

 

Emotional and financial impact among these 60-day survivors 

  • Nearly half reported being emotionally affected, and 6% sought mental health care
  • 37% reported a mild financial impact 
  • 10% reported use of most or all savings 
  • 7% reported having to ration food, heat, housing, or medications due to cost.

 

Source: https://www.acpjournals.org/doi/10.7326/M20-5661?mc_source=MTExMDY2Ojo6NTQwYWU1MjNmMDVkNDRlNDliOTJkZTA0MDkzOTcxMmY6OnYzOjoxNjA1MjI1MDcxOjox& 

 

If you are experiencing some of these symptoms after COVID-19 infection, please contact your primary care physician to get help:

  • Respiratory problems
  • Heart trouble 
  • Fever and Infection 
  • Gastrointestinal symptoms
  • Persistent weakness and inability to perform daily tasks
  • Neurological symptoms such as unclear thinking or poor awareness

 

About

Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation and immunological disorders. We also pioneer in R&D projects centered on integrating biomarker targets in all phases of drug development, from preclinical to post-marketing. Plexision’s technology can be adapted to

  • - Assess disease risk for several immunological disorders.
  • - Predict the success of a drug for a specific patient.
  • - Develop dosing recommendations for new immunological drugs.

Our state-of-the-art laboratory is CLIA-certified and located in Pittsburgh, PA.

Contact